AngioDynamics (NASDAQ:ANGO) CEO Purchases $111,500.00 in Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CEO James Clemmer bought 10,000 shares of the stock in a transaction dated Thursday, October 9th. The stock was bought at an average cost of $11.15 per share, with a total value of $111,500.00. Following the purchase, the chief executive officer owned 882,529 shares in the company, valued at $9,840,198.35. The trade was a 1.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

AngioDynamics Trading Down 1.3%

NASDAQ ANGO opened at $11.00 on Friday. AngioDynamics, Inc. has a 1-year low of $6.11 and a 1-year high of $13.50. The stock has a 50-day moving average of $10.16 and a 200-day moving average of $9.80. The firm has a market cap of $453.20 million, a PE ratio of -14.10 and a beta of 0.78.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. During the same quarter in the previous year, the company posted ($0.11) EPS. AngioDynamics’s revenue for the quarter was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, equities research analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANGO has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 4th. Lake Street Capital started coverage on AngioDynamics in a research report on Wednesday, July 16th. They set a “buy” rating and a $24.00 price target for the company. Canaccord Genuity Group upped their price target on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AngioDynamics in a research report on Wednesday, July 16th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently modified their holdings of ANGO. GAMMA Investing LLC lifted its holdings in shares of AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 12,891 shares during the period. Acuitas Investments LLC grew its position in shares of AngioDynamics by 9.7% during the first quarter. Acuitas Investments LLC now owns 442,230 shares of the medical instruments supplier’s stock valued at $4,153,000 after purchasing an additional 38,950 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of AngioDynamics by 25.1% during the first quarter. Principal Financial Group Inc. now owns 120,008 shares of the medical instruments supplier’s stock valued at $1,127,000 after purchasing an additional 24,047 shares in the last quarter. Cornerstone Investment Partners LLC purchased a new position in shares of AngioDynamics during the first quarter valued at about $169,000. Finally, Cerity Partners LLC grew its position in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock worth $121,000 after acquiring an additional 2,333 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.